Your browser doesn't support javascript.
loading
Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches.
Tomuleasa, Ciprian; Selicean, Cristina; Cismas, Sonia; Jurj, Anca; Marian, Mirela; Dima, Delia; Pasca, Sergiu; Petrushev, Bobe; Moisoiu, Vlad; Micu, Wilhelm-Thomas; Vischer, Anna; Arifeen, Kanza; Selicean, Sonia; Zdrenghea, Mihnea; Bumbea, Horia; Tanase, Alina; Grewal, Ravnit; Pop, Laura; Aanei, Carmen; Berindan-Neagoe, Ioana.
Afiliación
  • Tomuleasa C; a Department of Hematology , Ion Chiricuta Clinical Cancer Center , Cluj Napoca , Romania.
  • Selicean C; b Research Center for Functional Genomics and Translational Medicine/Hematology , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Cismas S; a Department of Hematology , Ion Chiricuta Clinical Cancer Center , Cluj Napoca , Romania.
  • Jurj A; c Department of Genetics , Victor Babes University of Medicine and Pharmacy , Timisoara , Romania.
  • Marian M; d Department of Hematology , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Dima D; e Research Center for Functional Genomics and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Pasca S; a Department of Hematology , Ion Chiricuta Clinical Cancer Center , Cluj Napoca , Romania.
  • Petrushev B; a Department of Hematology , Ion Chiricuta Clinical Cancer Center , Cluj Napoca , Romania.
  • Moisoiu V; e Research Center for Functional Genomics and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Micu WT; e Research Center for Functional Genomics and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Vischer A; e Research Center for Functional Genomics and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Arifeen K; e Research Center for Functional Genomics and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Selicean S; d Department of Hematology , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Zdrenghea M; d Department of Hematology , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Bumbea H; d Department of Hematology , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Tanase A; a Department of Hematology , Ion Chiricuta Clinical Cancer Center , Cluj Napoca , Romania.
  • Grewal R; d Department of Hematology , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Pop L; f Department of Hematology , Carol Davila University of Medicine and Pharmacy , Bucharest , Romania.
  • Aanei C; g Department of Hematology , University Clinical Hospital , Bucharest , Romania.
  • Berindan-Neagoe I; h Department of Stem Cell Transplantation , Fundeni Clinical Institute , Bucharest , Romania.
Crit Rev Clin Lab Sci ; 55(5): 329-345, 2018 08.
Article en En | MEDLINE | ID: mdl-29801428
Chronic lymphocytic leukemia (CLL) is a malignancy defined by the accumulation of mature lymphocytes in the lymphoid tissues, bone marrow, and blood. Therapy for CLL is guided according to the Rai and Binet staging systems. Nevertheless, state-of-the-art protocols in disease monitoring, diagnostics, and prognostics for CLL are based on the assessment of minimal residual disease (MRD). MRD is internationally considered to be the level of disease that can be detected by sensitive techniques and represents incomplete treatment and a probability of disease relapse. MRD detection has been continuously improved by the quick development of both flow cytometry and molecular biology technology, as well as by next-generation sequencing. Considering that MRD detection is moving more and more from research to clinical practice, where it can be an independent prognostic marker, in this paper, we present the methodologies by which MRD is evaluated, from translational research to clinical practice.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Neoplasia Residual Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Crit Rev Clin Lab Sci Asunto de la revista: TECNICAS E PROCEDIMENTOS DE LABORATORIO Año: 2018 Tipo del documento: Article País de afiliación: Rumanía Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Neoplasia Residual Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Crit Rev Clin Lab Sci Asunto de la revista: TECNICAS E PROCEDIMENTOS DE LABORATORIO Año: 2018 Tipo del documento: Article País de afiliación: Rumanía Pais de publicación: Reino Unido